Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Phases US Epinephrine Entry

Executive Summary

Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.

You may also be interested in...



Sandoz Seeks Help From Doctors For US Symjepi Push

Sandoz is encouraging US doctors to write prescriptions for epinephrine that include its Symjepi pre-filled syringes, and not just for auto-injector devices, as it targets the retail sector.

Sandoz Chalks Up A Third US Launch of 2019 With The First Generic Suprane

As it continues to shape its US portfolio towards more complex dosage forms, comprising biosimilars, value-added medicines and complex generics, Sandoz has announced its third launch of 2019 in the world’s largest market.

Sandoz Will Differentiate To Serve A Different World

A differentiated offering that includes biosimilars, value-added medicines and digital health technologies is central to Sandoz’ mission to improve both patient health and its own profit margins, according to CEO Richard Francis.

Related Content

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel